-

Harrow Health to Announce Second Quarter 2022 Financial Results on August 9, 2022

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow Health, Inc. (Nasdaq: HROW), an eye health pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medications that are accessible and affordable, today announced that it will release its financial results for the second quarter ended June 30, 2022, on Tuesday, August 9, 2022, after the market close. The Company will also post its second quarter Letter to Stockholders to the “Investors” section of its website, harrowinc.com. Harrow Health will host a conference call and live webcast at 4:45 p.m. Eastern Time to discuss the results and provide a business update.

Conference Call Details:

 

Date:

Tuesday, August 9, 2022

Time:

4:45 p.m. Eastern time

Participant Dial-in:

1-833-953-2434 (U.S.)

1-412-317-5763 (International)

Replay Dial-in (Passcode 8466369):

(telephonic replay through August 16, 2022)

1-877-344-7529 (U.S.)

1-412-317-0088 (International)

Webcast: (online replay through November 9, 2022)

harrowinc.com

 

About Harrow Health
Harrow Health, Inc. (Nasdaq: HROW) is an eye health pharmaceutical company focused on the development, production, sale, and distribution of innovative ophthalmic prescription medications that are accessible and affordable. For more information about Harrow Health, please visit the Investors section of the corporate website, harrowinc.com.

Contacts

Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737

Industry:

Harrow Health, Inc.

NASDAQ:HROW
Release Versions
English
$Cashtags
$HROW

Contacts

Jamie Webb, Director of Communications and Investor Relations
jwebb@harrowinc.com
615-733-4737

More News From Harrow Health, Inc.

Harrow Enters into Commercialization Agreement with Samsung Bioepis for Ophthalmology Biosimilars Portfolio in the United States

NASHVILLE--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that it has entered into a definitive agreement with Samsung Bioepis Co. Ltd. (hereafter “Samsung Bioepis”) to secure the exclusive U.S. commercial rights to the ophthalmology biosimilar portfolio of Samsung Bioepis — BYOOVIZ® (ranibizumab-nuna), an FDA-approved biosimilar referencing LUCENTISi (ranibizumab), and OPUVIZ™ (aflibercept-yszy), an FDA-approved biosimilar refer...

Harrow Appoints Mike Biega as Vice President of Investor Relations and Communications

NASHVILLE, Tenn.--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that Mike Biega has joined Harrow as Vice President of Investor Relations and Communications, succeeding Jamie Webb, Director of Communications and Investor Relations, who recently announced her retirement. Jamie will remain in her role into August to support a smooth and effective transition. “We are excited to welcome Mike to the Harrow Family. His wealth of exper...

Harrow Acquires U.S. Commercial Rights to BYQLOVI™ (Clobetasol Propionate Ophthalmic Suspension) 0.05% from Formosa Pharmaceuticals

NASHVILLE, Tenn. & TAIPEI, Taiwan--(BUSINESS WIRE)--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, and Taiwan-based Formosa Pharmaceuticals (“Formosa”, 6838.TW), today announced a licensing agreement, whereby Harrow has acquired the exclusive U.S. commercial rights for BYQLOVI™ (clobetasol propionate ophthalmic suspension) 0.05%. BYQLOVI was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of post-operative inflammation and pain...
Back to Newsroom